Earnings ·
Atrium Therapeutics reported second quarter 2026 financial results on August 13, 2026
RNAAtrium Therapeutics, Inc.
Atrium Therapeutics reported second quarter 2026 financial results on August 13, 2026. The company earned a $15 million milestone payment from Bristol Myers Squibb under their global cardiovascular collaboration and recognized $3.0 million in collaboration revenue primarily related to R&D services. For the quarter ended June 30, 2026, research and development expenses were $15.3 million and general and administrative expenses were $10.3 million, resulting in a net loss of approximately $20.2 million. As of June 30, 2026, the company held $263.9 million in cash, cash equivalents, and short-term investments, which management believes is sufficient to fund operations through mid-2028. The filing also highlighted FDA clearance for the IND application for ATR 1072 and the launch of the Corventis Phase 1/2 trial in PRKAG2 syndrome. Atrium Therapeutics operates as a biopharmaceutical company developing RNA therapeutics targeted to the heart.